HAVN Life Sciences Inc.

OTC: HAVLF · Healthcare · Biotechnology

Canadian filerHQ Port Moody, BCReports USD

#984 of 1,394 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 17

v0.1 · 5/100 weight · pillars only

↑ balance-sheet leverage, Piotroski F · ↓ return on equity, market scale

Methodology →

Revenue TTM

$451.3k

Rev growth YoY (TTM)

+843.3%

Net income (FY)

-$17.9M

Employees

Market cap

$2.6k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$220.4k276.5k CAD2022

Net income-$17.9M-22.4M CAD2022

Operating income-$7.8M-9.8M CAD2022

Total assets$3.2M4.1M CAD2022

Liabilities$718.0k918.5k CAD2022

Equity$2.5M3.1M CAD2022

Revenue trend

FY2020 – FY2022 · USD

FY20

FY21

$220.4k

FY22

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

HAVN Life Sciences Inc. booked $220.4k in FY2022 revenue — among the slowest-growing Healthcare companies we track, at a -8117.8% net margin.

Peers · Healthcare

SheerVision, Inc.——Southwestern Medical Solutions, Inc.——Syros Pharmaceuticals, Inc.——Global Hemp Group Inc.——

Key facts

CEOTim Moore

SectorHealthcare

IndustryBiotechnology

HeadquartersPort Moody, BC

ExchangeOTC: HAVLF

Employees6

IPO date2021-01-08

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.